ADEPTRIX aims to improve patient outcomes through the development of CSF and blood-based biomarkers that are more sensitive and informative than current immunoassays. We are targeting the diagnosis and treatment of Alzheimer’s Disease and related dementias through the development of innovative molecular tests that are simple, precise, and affordable. Our core technology BAMS (Bead Assisted Mass Spectrometry) combines the specificity of an immunoassay with the resolution of mass spectrometry. Established in 2012, Adeptrix holds several patents surrounding the BAMS platform. We’ve used this proprietary technology over the past 12 years to develop reagents and assays for a variety of collaborators across academia, biotechnology, pharma, and analytical testing labs in fields including but not limited to: Oncology, Neurology, Virology, and Epigenetics. The team at Adeptrix can act as a service provider or work collaboratively with you to reach your project/clinical goals. We currently have assays that can evaluate the relative quantities of up to 40 amyloid beta peptides, detect multiple forms of total and phospho-Tau, and an assay for alpha synuclein in the pipeline.